Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:712549.
doi: 10.1155/2010/712549. Epub 2010 Mar 31.

Duration of suppression of adrenal steroids after glucocorticoid administration

Affiliations

Duration of suppression of adrenal steroids after glucocorticoid administration

John S Fuqua et al. Int J Pediatr Endocrinol. 2010.

Abstract

Hydrocortisone has long been the treatment of choice for congenital adrenal hyperplasia (CAH). However, treatment with this medication remains problematic. Patients with 21-hydroxylase deficiency CAH have significant diurnal variation in the secretion of 17-hydroxyprogesterone (17OHP). When considering treatment strategies, this variation must be considered along with the pharmacokinetic and pharmacodynamic properties of exogenous glucocorticoids. Orally administered hydrocortisone is highly bioavailable, but it has a short time to maximum concentration (T(max)) and half life (T(1/2)). While prednisone has a somewhat longer T(max) and T(1/2), they remain relatively short. There have been several studies of the pharmacodynamics of hydrocortisone. We present data indicating that the maximum effect of hydrocortisone in CAH patients is seen 3 hours after a morning dose. After an evening dose, suppression of adrenal hormones continues until approximately 0500 the next day. In both situations, however, there is a large degree of intersubject variability. These data are consistent with earlier published studies. Use of alternate specimen types, possibly in conjunction with delayed release hydrocortisone preparations under development, may allow the practitioner to design a medication regimen that provides improved control of androgen secretion. Whatever dosing strategy is used, clinical judgment is required to ensure the best outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pharmacokinetic profile following the morning administration of intravenous and oral doses of hydrocortisone in 16 subjects with CAH, at a median age of 10.6 years. Figure taken from [12]. Society for Endocrinology, 2001. Used with permission.
Figure 2
Figure 2
Serum concentrations of 17-hydroxyprogesterone, androstenedione, and testosterone after administration of hydrocortisone in the morning. *P < .05 compared to baseline.
Figure 3
Figure 3
Serum concentrations of 17-hydroxyprogesterone, androstenedione, and testosterone after administration of a nighttime dose of hydrocortisone. *P = .05 compared to baseline.

References

    1. Metzger DL, Wright NM, Veldhuis JD, Rogol AD, Kerrigan JR. Characterization of pulsatile secretion and clearance of plasma cortisol in premature and term neonates using deconvolution analysis. Journal of Clinical Endocrinology and Metabolism. 1993;77(2):458–463. - PubMed
    1. Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, Rogol AD. Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. Journal of Clinical Endocrinology and Metabolism. 1993;76(6):1505–1510. - PubMed
    1. Darzy KH, Shalet SM. Absence of adrenocorticotropin (ACTH) neurosecretory dysfunction but increased cortisol concentrations and production rates in ACTH-replete adult cancer survivors after cranial irradiation for nonpituitary brain tumors. Journal of Clinical Endocrinology and Metabolism. 2005;90(9):5217–5225. - PubMed
    1. Selmaoui B, Touitou Y. Reproducibility of the circadian rhythms of serum cortisol and melatonin in healthy subjects: a study of three different 24-h cycles over six weeks. Life Sciences. 2003;73(26):3339–3349. - PubMed
    1. Atherden SM, Barnes ND, Grant DB. Circadian variation in plasma 17-hydroxyprogesterone in patients with congenital adrenal hyperplasia. Archives of Disease in Childhood. 1972;47(254):602–604. - PMC - PubMed

LinkOut - more resources